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Abstract: Lymphatic vasculature in solid tumors may serve as the pathway for metastatic spread of the cancer to the regional
lymph nodes and to distant organs. Controversy still exists whether tumors metastasize through existing lymphatics or through
newly formed vessels (lymphangiogenesis). The role of lymphangiogenesis in lymphoma spread and proliferation is not clearly
established. VEGF-C is the most potent inducer of lymphangiogenesis. LYVE-1 was shown to be a specific marker for
lymphatic vessels in normal and tumor tissue. The aim of the present study was the evaluation of lymph node LYVE-1-positive
lymphatic sinus density (LSD) and VEGF-C expression in patients with non-Hodgkin’s lymphoma (nHL) and in reactive lymph
nodes. Sixty paraffin-embedded lymph nodes from newly diagnosed patients with B-cell nHL were evaluated. Twelve lymph
node biopsy specimens from adult patients with reactive lymphonodulitis were used as controls. Sections of lymph nodes were
stained immunohistochemically for LYVE-1 and VEGF-C. VEGF-C expression in lymph nodes of nHL patients was low and
not significantly different from that in the control (p=0.6). Moreover, VEGF-C expression did not differ significantly between
aggressive and indolent lymphomas (p=0.53). Similarly we did not find differences in LSD in aggressive nHL and in indolent
nHL (p=0.49). The mean LSD in reactive lymph nodes was higher than in nHL (p=0.03). Only in 2 out of 12 reactive lymph
nodes LYVE-1-positive vessels were absent. In all groups we demonstrated a strong positive correlation between VEGF-C
and LYVE-1 expression (p= 0.0001). Higher LSD in reactive lymph nodes as compared to those of nHL patients suggests that
lymphoma proliferation leads to the destruction of the existing lymphatics rather than to lymphangiogenesis within lymph
nodes. NHL are not associated with increased expression of VEGF-C nor increased LYVE-1-positive lymphatic sinuses density
within lymph nodes. (www.cm-uj.krakow.pl/FHC)
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Introduction
Lymphangiogenesis is a formation of new lymphatic
vessels from preexisting capillaries. The development of
lymphatic vessels depends upon interactions between
lymphatic endothelium and signaling molecules derived
from serum and extracellular matrix. Vascular endothe-
lial growth factors (VEGFs) family of glycoproteins is
essential for angiogenesis and lymphangiogenesis.
Among these proteins, VEGF-C and VEGF-D are the
most potent inducers of lymphangiogenesis. VEGF-C
stimulates lymphangiogenesis by binding to VEGFR-2
and VEGFR-3 receptors on lymphatic endothelial cells
[13, 29, 30]. Increased VEGF-C expression correlates
with increased risk of metastasis in regional lymph
nodes in many solid tumors. 
The role of lymphangiogenesis in the development
of cancer and tumor metastasis is, however, still con-
troversial. It has been proposed that tumors may stimu-
late lymphatic endothelium proliferation in analogous
way as in tumor angiogenesis. Animal model studies
have confirmed that VEGF-C produced by tumor cells
promotes lymphangiogenesis and lymph nodes meta-
stasis [15, 29]. Non-Hodgkin’s lymphomas (nHL) can
spread via blood vasculature or lymphatics. Lymphoma
cells may infiltrate the lymph nodes, surrounding tissue
or migrate to other organs. Angiogenesis in haemato-
logical malignancies was a subject of intensive research
in the last years. Increased microvessel density (MVD)
was demonstrated in nHL [17, 20]. However the rela-
tionships between MVD and histologic subtypes of lym-
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phoma are not clear. Elevated serum levels of proan-
giogenic cytokines (i.e. VEGF) are the independent
prognostic factor in nHL [24]. Data concerning the role
of lymphangiogenesis in nHL are very limited. Salven
et al. showed low VEGF-C mRNA in lymphoma cells
[23]. Studies of tumor lymphangiogenesis have been
hampered by the lack of specific and reliable markers
for lymphatic endothelium. LYVE-1, a CD44 homo-
logue, and hyaluronan (HA) receptor predominantly
expressed on lymphatic endothelium was shown to be a
specific marker for lymphatic vessel in normal and
tumor tissues. It is also abundant in lymph nodes, espe-
cially in high endothelial venules [1, 34]. LYVE-1 plays
a crucial role not only in HA binding and metabolism
but also in leukocyte trafficking within lymphatic ves-
sels and lymph nodes. LYVE-1 interaction with HA may
facilitate tumor cells attachment and enhance lymphoma
growth and dissemination.
The aim of the present study was the evaluation of
LYVE-1-positive lymphatic sinus density (LSD) and
VEGF-C expression in lymph nodes of patients with
nHL and in control reactive lymph nodes.
Materials and methods
Sixty paraffin-embedded lymph nodes from newly diagnosed pa-
tients with B-cell nHL were evaluated (22 aggressive and 38 indolent
nHL). In addition, 12 lymph node biopsy specimens from adult
patients with reactive lymphonodulitis were used as controls. The
lymphoma group consisted of 24 females and 36 males, median age
62 years (range 27-70 years). Diagnosis of lymphoma was made
according REAL/WHO classification [9]. Aggressive nHL group
consisted of 11 cases of diffuse large B-cell lymphoma, 4 cases of
follicular lymphoma G3, 3 cases of mantle cell lymphoma, 2 cases
of Burkitt lymphoma and 2 cases of lymphoblastic lymphoma.
Indolent nHL group consisted of 20 cases of follicular lymphoma
G1/G2, 12 cases of small lymphocytic lymphoma, 4 cases of nodal
marginal zone lymphoma and 2 cases of lymphoplasmacytoid lym-
phoma.
Lymph node sections were stained immunohistochemically for
LYVE-1 and VEGF-C. The studied samples were fixed in 10%
buffered formalin and subsequently embedded in paraffin. The sec-
tions were stained with hematoxylin and eosin and evaluated histo-
pathologically. Deparaffinised sections were pre-treated with Target
Retrieval Solution (DakoCytomation, Denmark) at 95˚C for 20 min.
Following a wash in Tris-buffered saline (TBS), they were treated
with 3% H2O2 for 10 min, washed in distilled H2O (10 min) and PBS
(5 min), and incubated with mouse monoclonal antibodies against
LYVE-1 (RELIATech GmbH, Germany) (diluted 1:200) or against
VEGF-C goat polyclonal antibody (C-20, catalog no. sc-1881; Santa
Cruz Biotechnology, USA) for 60 min at room temperature. For all
slides, a wash in TBS was followed by treatment with peroxidase-
labeled polymer conjugated to goat anti-rabbit, anti-mouse or anti-
goat immunoglobulins (Universal LSABTM+ Kit; DakoCytomation,
Denmark) for 30 min at room temperature. Immunostaining was
visualized with diaminobenzidine tetrahydrochloride (DAB; Da-
koCytomation, Denmark) and then the sections were counter-
stained with hematoxylin. In each case the negative control was
included using Primary Negative Control (DakoCytomation,
Denmark) [11, 26].
For the evaluation of lymphatic sinus density (LSD) within
lymph nodes, slides were scanned in the light microscope (Olympus
BX-41) at × 40 magnification and three areas of maximal LVD,
so-called "hot spots" were identified. In each hot spot (each field
representing an area of 0.375 mm2), lymphatic sinuses were counted
at × 400 magnification by two independent investigators.
Intensity of immunocytochemical expression of VEGF-C was
evaluated using the ImmunoReactive Score (IRS) according to Rem-
mele and Stenger [19]. The applied scale took into account both
intensity of the colour reaction and percentage of cells, which ex-
hibited the positive reaction (Table 1). The final result represented
the product of the two parameters and its value ranged from 0 to 12.
Statistical analysis was carried out using the Mann-Whitney U-test,
Anova Kruskall Wallis test and Spearman test. Differences were
considered statistically significant at p<0.05. 
Results
VEGF-C was expressed in the cytoplasm of lympho-
ma cells infiltrating lymph nodes and in lymphocytes
in reactive lymphonodulitis. We demonstrated
LYVE-1-positive reaction on endothelium of lym-
phatic sinuses and some high endothelial venules in
lymph nodes irrespectively of initial diagnosis (lym-
phoma or reactive lymph nodes) (Figs. 1, 2). Statisti-
cal analysis showed that VEGF-C expression in lymph
nodes of nHL patients was low and not significantly
different from that in the control: the mean IRS 2
(range 0-6) and 2 (range 0-6) respectively (p=0.6).
Moreover, VEGF-C expression did not differ signifi-
cantly between aggressive and indolent lymphomas:
mean IRS 2 (0-6) and 1, respectively (0-6) (p=0.53).
Similarly, we did not find differences in LSD in ag-
gressive nHL - 3 (0-27) and in indolent nHL - 2.6
(0-11) (p=0.49). The mean LSD in reactive lymph
nodes was higher than in nodes of nHL patients: 8.4
(range 0 - 21) and 2.8 (range 0-27), respectively
(p=0.03). Only in 2 out of 12 reactive lymph node
specimens LYVE-1-positive vessels were absent. In all
groups we demonstrated strong positive correlation be-
tween VEGF-C and LYVE-1 expression (p= 0.0001). 
We correlated VEGF-C and LSD visualized by
LYVE-1 expression with some well known parameters
of prognosis in nHL such as histological subtypes (ag-
gressive versus indolent), clinical stage of disease and
dehydrogenase lactate (LDH) activity. We found no
statistically significant correlations for these parameters.
The association between LSD, VEGF-C and clinicopa-
thological data are shown in Table 2.
Table 1. Evaluation of the reaction results using the ImmunoReac-
tive Score (IRS) scale
% positive cells Intensity of the reaction
0 no positive cells 0 no positive reaction
1 <10% positive cells 1 faint colour reaction
2 10-50% positive cells 2 moderate colour reaction
3 51-80% positive cells 3 intense colour reaction
4 >80% positive cells
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Discussion
The lymphatic vasculature may serve as a pathway for
metastatic spread of cancer to the regional lymph nodes
and to distant organs. Controversy still exists whether
tumors metastasize through the existing lymphatics or
through newly formed vessels. Recently, LYVE-1 (lym-
phatic endothelium hyaluronan receptor) has been ident-
ified as a powerful marker for lymphatic endothelium.
LYVE-1 is also expressed by a subset of infiltrating
macrophages found in tumors, liver blood sinusoids, and
high endothelial venules in lymph nodes and spleen [4,
12, 34]. Little is known about the biology of the lympha-
tics in tumors and the regulation of tumor induced lym-
phangiogenesis. Several studies were focused on
assessment of lymphatic vessel density in and around
tumors. The data concerning the prognostic significance
of intra- and peritumoral lymphangiogenesis are confus-
ing. There is increasing evidence based on animal model
that metastatic spread occurs via peritumoral rather than
intratumoral lymphatics [18]. Moreover, intratumoral
lymphatics are not features of all tumor types. Williams
et al. [33] reported the absence of lymphatic vessels
within both tumor and surrounding areas. In solid tu-
mors, immunohistochemical studies with anti-LYVE-1
antibodies resulted in different findings in various tumor
types. Trojan et. al. [31] reported lack of lymphan-
giogenesis in prostate cancer. LYVE-1-positive lym-
phatic vessels were detected at the tumor periphery of
endometrial and lung cancers but not within the main
tumor mass [14]. Peritumoral but not intratumoral
LYVE-1-positive vessels were identified in the majority
of breast carcinoma cases [3, 32]. In head and neck
squamous cell carcinoma, increased number of intratu-
moral lymphatics was associated with the status of re-
gional lymph node metastasis. The presence of
intratumoral lymphatic vessels was also shown in mela-
noma [6, 16, 27]. 
VEGF-C enhances lymphangiogenesis and promotes
metastasis via lymphatic vessels. Several studies have
shown a correlation between VEGF-C expression and
lymph node metastases. There is convincing evidence
that VEGF-C expression is upregulated in many solid
tumors [10, 28]. VEGF-C is expressed not only on tumor
cells but also on stromal cells including macrophages.
Inflammation or cancer induce recruitment of macro-
phages and overproduction of VEGF-C [25]. Further-
more, VEGF-C itself may induce macrophage
chemotaxis [27, 28]
Non-Hodgkin’s lymphomas are heterogenous group
of lymphoid malignancies with different clinical course.
NHLs represent the malignant counterparts of normal
lymphocytes, arrested at specific stages of maturation.
Lymphocytes enter lymphatic capillaries and migrate
through the lymphatic vessels to the lymph nodes. Indol-
ent lymphomas related to small resting lymphocytes
usually are disseminated at presentation, whereas ag-
gressive lymphomas related to activated lymphocytes
are often initially localized [2]. The role of lymphan-
giogenesis in lymphoma dissemination remains to be
determined. In murine model of Burkitt’s lymphoma,
overexpression of c-Myc in B lymphocytes resulted in
increasing density of lymphatics (sinuses and vessels)
within lymph nodes [21]. The importance of CD44 in
the biology of lymphoma is well established. In diffuse
large B cell lymphoma, increased expression of CD44
correlates with lymphoma dissemination [7, 8]. Structu-
ral and functional similarities between CD44 and
LYVE-1 prompted us to investigate LYVE-1 expression
within lymph nodes in lymphoma patients. Our study
has been focused on the assessment of lymphatic sinus
density in lymph nodes by LYVE-1 immunohistochem-
Fig. 2. VEGF-C expression in lymphoma lymph node (Large B-cell
lymphoma). × 400.
Fig. 1. LYVE-1-positive lymphatic sinuses in reactive lymph node.
× 200.
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istry and on VEGF-C expression in lymph nodes. We
analyzed LSD and VEGF-C expression in a variety of
histological subtypes and clinical aggressiveness of
lymphoma. We demonstrated that expression of VEGF-
C, the most potent cytokine stimulating lymphangiogen-
esis, was not increased in lymph nodes of lymphoma
patients when compared to reactive lymph nodes. Ac-
cording to Salven et al. [23], low expression of VEGF-C
in nHL may reflect the cell-specific pattern of expression
of the VEGF-C gene in the corresponding normal cells.
We found no correlation between VEGF-C expression
and clinical stage of lymphoma or widely used prognos-
tic factor such as LDH activity. On the other hand, in all
groups we observed a strong positive correlation be-
tween VEGF-C and LSD. This observation confirms
the role of VEGF-C as an inducer of the development
of lymphatic vasculature. Higher LSD in reactive
lymph nodes than in nHL lymph nodes suggests that
lymphoma proliferation leads to destruction of the
existing lymphatics rather than to lymphangiogenesis
within lymph nodes. Moreover, increased LSD with
relatively low VEGF-C expression in reactive lymph
nodes indicates other mechanisms stimulating prolife-
ration of lymphatic endothelium. Recently Cursiefen et
al. [5] have demonstrated that inflammatory lymphan-
giogenesis may be indirectly stimulated by VEGF-A
via macrophage recruitment. In conclusion, nHLs are
not associated with increased expression of VEGF-C
or increased LYVE-1-positive lymphatic sinus den-
sity within lymph nodes.
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